Altabax - 2007 FDA approvals

Drug: Altabax (retapamulin)
Indication: Impetigo
Company: GlaxoSmithKline
Approval Date: April 12, 2007

Scoop: Altabax is a topical treatment of impetigo, an infection of the top layers of the skin that typically occurs in infants and children 2 to 6 years of age. Altabax is the first new class of prescription topical antibacterials--called pleuromutilins-- which inhibit bacterial protein synthesis and are active against a variety of pathogenic bacteria.

Altabax - 2007 FDA approvals
Read more on

Suggested Articles

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.

While screening Caenorhabditis elegans for genetic clues to the PI3K/Akt signaling pathway, scientists found a key protein for insulin synthesis.